1 BTC
=
- USD
Rhythm Pharmaceuticals, Inc. Common Stock
As of June 19, 2026 at 23:43 UTC
Chart
About Rhythm Pharmaceuticals, Inc. Common Stock
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company engaged in the development and commercialization of therapies for patients with rare neuroendocrine diseases. The company is focused on advancing its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. In addition, it has two early-stage investigational MC4R agonists in clinical development, RM-718 and bivamelagon, designed not to cause hyperpigmentation. The company is also focused on advancing potential candidates for congenital hyperinsulinism. It currently operates in two business segments: the United States, which generates maximum revenue, and International.
RYTM in Bitcoin terms
Rhythm Pharmaceuticals, Inc. Common Stock is tracked on Roxom Terminal for users who want to follow and trade global stocks in a Bitcoin-denominated market environment.
- Rhythm Pharmaceuticals, Inc. Common Stock is categorized under PHARMACEUTICAL PREPARATIONS.
- BTC-denominated charting frames stock performance against Bitcoin instead of fiat alone.
- The global terminal hub links individual stock pages into a crawlable BTC-native market map.
Market Statistics
Trading Metrics
How to Buy RYTM
Create Your Account
Sign up, deposit BTC, and transfer it to your Unified Trading Account. It only takes a moment.
Start Your Trade
From Terminal, click Trade Now on the asset you want to buy. You'll be purchasing its tokenized asset.
Buy RYTM
Enter the amount and confirm your purchase. That's it! You'll see the impact of the trade in your Unified Trading Account.
New to Tokenized Assets? Learn more in our Help Center.
Latest News
5 articlesRhythm Pharmaceuticals (NASDAQ: RYTM) stock surged 5.47% after presenting six-month Phase 2 trial data for setmelanotide in Prader-Willi syndrome patients. The study showed meaningful improvements in BMI (3.06% mean reduction), body composition, hyperphagia, and behavioral measures, with a consistent safety profile. The trial enrolled 18 patients aged 6-23, with 17 remaining on active treatment.
Rhythm Pharmaceuticals announced that seven presentations, including four late-breaking abstracts, have been accepted for The Endocrine Society's Annual Meeting (ENDO 2026) in Chicago from June 13-16, 2026. The presentations will showcase clinical trial data for setmelanotide and bivamelagon in treating rare neuroendocrine diseases including Prader-Willi syndrome, acquired hypothalamic obesity, and Bardet-Biedl syndrome. The company will also host its inaugural MOMENTUM meeting on June 12 to discuss advances in MC4R pathway diseases.
Rhythm Pharmaceuticals announced that its Chairman, President and CEO David Meeker and CFO Hunter Smith will participate in fireside chats at the Jefferies Global Healthcare Conference (June 4, 2026) and Goldman Sachs 47th Annual Global Healthcare Conference (June 8, 2026), respectively. The company's lead asset IMCIVREE (setmelanotide) is an FDA-approved MC4R agonist for treating rare obesity conditions including acquired hypothalamic obesity and genetic syndromes like Bardet-Biedl syndrome.
Green Thumb Industries has filed for DEA registration following the rescheduling of marijuana to Schedule III, positioning itself as a first-mover in the evolving U.S. cannabis landscape. The move could attract institutional investors, enable research partnerships, and potentially lead to major stock exchange listings if recreational cannabis is also rescheduled. CEO Ben Kovler emphasized that this strategic action normalizes the federal cannabis industry.
Rhythm Pharmaceuticals announced the appointment of Kim Popovits, an accomplished life sciences leader with 40+ years of experience, to its Board of Directors, replacing departing board member Ed Mathers who served since 2013. Popovits brings extensive expertise in commercialization, reimbursement, and governance from her previous roles at Genomic Health and Genentech.